Monte Rosa Therapeutics (NASDAQ:GLUE) reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory
This under-the-radar fintech stock boasts a Superscore of 74 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
SKYX Platforms (NASDAQ:SKYX) Chief Executive Officer Lenny Sokolow outlined the company’s product strategy, planned merger with smart-home device provider Deako, and expansion efforts during Noble Capital Markets’ Virtual Equity Conference.
Sokolow said SKYX is focused on plug-and-play electrical p
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environmen...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Kaltura (NASDAQ:KLTR) outlined its strategy to expand beyond enterprise video software into AI-driven conversational and personalized digital experiences during a presentation hosted by Noble Capital Markets.
Ron Yekutiel, Kaltura’s president and CEO, said the company has operated for 20 years as a
